I had not heard of NWBO back when all these different trials were being considered. It seems to me that the company chose to go after the toughest targets as none of the others have the complication of the brain-blood barrier. Limited funds may have been the reason, but I also think that they knew that if they could be effective in the brain it's very likely that they would be effective elsewhere. Gary